Edition:
United Kingdom

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

3.11USD
22 Feb 2019
Change (% chg)

$0.08 (+2.64%)
Prev Close
$3.03
Open
$3.06
Day's High
$3.11
Day's Low
$3.02
Volume
3,330
Avg. Vol
7,593
52-wk High
$3.40
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

NGP Agreed To Provide Credit Up To $5 Mln To Evoke Pharma After NDA Approval Of Gimoti
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA INC - NGP HAS AGREED TO PROVIDE A LINE OF CREDIT OF UP TO $5.0 MILLION TO COMPANY FOLLOWING NDA APPROVAL OF GIMOTI.EVOKE PHARMA INC - NGP WILL RECEIVE A LOW SINGLE DIGIT PERCENTAGE ON NET SALES OF GIMOTI IN LIEU OF ANY INTEREST ON LINE OF CREDIT.  Full Article

Evoke Pharma Signs Agreement For Gimoti In The U.S. With Novos Growth Partners
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA SIGNS COMMERCIAL AND FINANCIAL AGREEMENT FOR ITS LEAD PRODUCT GIMOTI™ IN THE U.S. WITH NOVOS GROWTH PARTNERS.EVOKE PHARMA INC - EVOKE WILL RETAIN GREATER THAN 80% OF PRODUCT PROFITS FOLLOWING APPROVAL.EVOKE PHARMA INC - EVOKE MAINTAINS OWNERSHIP OF GIMOTI NEW DRUG APPLICATION.EVOKE PHARMA INC - EVOKE WILL MAINTAIN LEGAL, REGULATORY, AND MANUFACTURING RESPONSIBILITIES.EVOKE PHARMA INC - EVOKE WILL ALSO RETAIN A CONTRACT SALES ORGANIZATION, WHICH WOULD BE MANAGED BY NGP AND WHO WILL FINANCE WORKING CAPITAL FOR LAUNCH.EVOKE PHARMA INC - EVOKE WILL RECORD SALES FOR GIMOTI AND RETAIN MORE THAN 80% OF PRODUCT PROFITS.EVOKE PHARMA - NGP TO RECEIVE A PERCENTAGE OF PRODUCT PROFITS IN MID TO HIGH TEENS AS SERVICE FEE ONCE GIMOTI NET SALES SURPASS COMMERCIALIZATION COSTS.EVOKE PHARMA INC - TERM OF AGREEMENT IS FIVE YEARS.EVOKE PHARMA INC - GIMOTI IS EXPECTED TO BE LAUNCHED IN UNITED STATES DURING 2019, IF APPROVED BY FDA.EVOKE PHARMA INC - AS OF DECEMBER 31, 2018, EVOKE HAD APPROXIMATELY $5.3 MILLION IN CASH.EVOKE PHARMA INC - U.S. FDA HAS SET A TARGET GOAL DATE UNDER PHARMACEUTICAL DRUG USER FEE ACT OF APRIL 1, 2019.  Full Article

Evoke Announces FDA Submission Of New Drug Application For Gimoti™
Monday, 4 Jun 2018 

June 4 (Reuters) - Evoke Pharma Inc ::EVOKE ANNOUNCES FDA SUBMISSION OF NEW DRUG APPLICATION FOR GIMOTI™.EVOKE PHARMA INC - EXPECTS TO RECEIVE NOTIFICATION FROM FDA FILING WAS ACCEPTED FOR SUBSTANTIVE REVIEW IN EARLY AUGUST 2018.  Full Article

Evoke Pharma Posts Loss Of $0.13 Per Share in Q1
Monday, 14 May 2018 

May 14 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS FIRST QUARTER 2018 RESULTS AND HIGHLIGHTS.Q1 LOSS PER SHARE $0.13.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.NDA SUBMISSION FOR GIMOT ON TRACK FOR Q2 OF 2018.INCLUDED IN NET LOSS FOR Q1 WAS A GAIN OF ABOUT $433,000 DUE TO CHANGE IN FAIR VALUE OF WARRANT LIABILITY.  Full Article

Evoke Announces Agreement With Mallinckrodt To Amend Milestone Payments
Monday, 26 Mar 2018 

March 26 (Reuters) - Evoke Pharma Inc ::EVOKE ANNOUNCES AGREEMENT WITH MALLINCKRODT TO AMEND MILESTONE PAYMENTS.‍HAS AMENDED CO'S AGREEMENT WITH MALLINCKRODT, ARD INC. TO DEFER DEVELOPMENT AND APPROVAL MILESTONE PAYMENTS FOR GIMOTI​.AMENDED AGREEMENT DEFERS AMOUNT AND TIMING OF TWO MILESTONE PAYMENTS​.‍AMENDED AGREEMENT DEFERS AMOUNT AND TIMING OF TWO MILESTONE PAYMENTS DUE UPON U.S. FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION​.EVOKE PHARMA - HAVE IMPROVED CASH RUNWAY TO JANUARY OF NEXT YEAR AND REMAIN ON TRACK TO SUBMIT GIMOTI NDA NEXT QUARTER.  Full Article

Evoke Pharma reports Q3 loss per share $0.34
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Evoke Pharma Inc ::Evoke Pharma reports third quarter 2017 results and highlights.Q3 loss per share $0.34.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma signs commercial agreement with Thermo Fisher Scientific
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Evoke Pharma Inc ::Signs commercial agreement with Thermo Fisher Scientific.Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti​.Under five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke's potential commercial efforts​.  Full Article

Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Evoke Pharma Inc ::Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™.Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018​.Evoke Pharma Inc- ‍relative to safety, all gimoti doses were well‑tolerated.  Full Article